OptimizeRx Corporation (OPRX) Stock

About OptimizeRx Corporation

OptimizeRx Corporation is led by CEO Stephen L. Silvestro, employs 128 people, headquartered in US, publicly traded since 2007.

OptimizeRx Corporation (OPRX) stock trades at $9.15 with a market capitalization of $172.35M. The stock is valued at a price-to-earnings (P/E) ratio of 35.18, price-to-book of 1.23, price-to-sales of 1.63. Over the past 52 weeks the stock has ranged between $4.54 and $22.25, and currently trades 58.9% below its 52-week high.

On profitability, OptimizeRx Corporation generates a return on equity (ROE) of 3.60%, return on capital employed of 7.31%, an operating margin of 11.01%, a net profit margin of 4.66%.

OptimizeRx Corporation by the numbers, 2016–2025

Between 2016 and 2025 OptimizeRx Corporation reported revenue of $8.0M rising to $109.0M, a change of +1262.5% across 10 years. Compounded, revenue has grown 20.4% a year over five years, 20.7% over three, 18.5% over the last twelve months. Net profit rose to $5.0M.

Operating margin went from -20.4% in 2016 to 11.0% in 2025, a gain of 31.4 percentage points. The most recent net margin is 4.66%. On a trailing twelve-month basis to Jun '26, revenue is $99.0M and net profit $5.0M.

Borrowings stand at $26.0M, cash from operations was $19.0M in the latest year, positive in 5 of the last 10.

Return on equity has averaged -7.2% over five years, and was 3.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

OptimizeRx Corporation (OPRX) — frequently asked questions